Results 31 to 40 of about 13,127 (167)

Theoretical Insights into the Effect of Halogenated Substituent on the Electronic Structure and Spectroscopic Properties of the Favipiravir Tautomeric Forms and Its Implications on the Treatment of COVID-19 [PDF]

, 2020
In this study, we systematically investigated the electronic structure, spectroscopic (nuclear magnetic resonance, infrared, Raman, electron ionization mass spectrometry, UV-Vis, circular dichroism, and emission) properties, and tautomerism of ...
Felipe, La Porta, Teodorico, Ramalho, Letícia, Assis, Alexandre A., de Castro, João Paulo A., de Jesus   +4 more
core   +1 more source

Favipiravir (T-705) inhibits Junín virus infection and reduces mortality in a guinea pig model of Argentine hemorrhagic fever. [PDF]

PLoS Neglected Tropical Diseases, 2013
Junín virus (JUNV), the etiologic agent of Argentine hemorrhagic fever (AHF), is classified by the NIAID and CDC as a Category A priority pathogen. Presently, antiviral therapy for AHF is limited to immune plasma, which is readily available only in the ...
Brian B Gowen, Terry L Juelich, Eric J Sefing, Trevor Brasel, Jennifer K Smith, Lihong Zhang, Bersabeh Tigabu, Terence E Hill, Tatyana Yun, Colette Pietzsch, Yousuke Furuta, Alexander N Freiberg   +11 more
doaj   +1 more source

Angioedema after favipiravir treatment: Two cases

, 2022
Drug-induced angioedema often affects elderly patients with chronic drug use. Proper diagnosis and prompt with effective treatment reduce mortality.
Mehmet Sami Islamoglu, Mehmet Dokur, İslamoğlu, Mehmet Sami, Burak Onal, Börkü Uysal, Betül, Dokur, Mehmet, Betul Borku Uysal, Önal, Burak   +7 more
core   +1 more source

STUDI EFEKTIVITAS DAN EFEK SAMPING FAVIPIRAVIR PADA PASIEN COVID-19 PNEUMONIA DI RUMAH SAKIT BHAYANGKARA SURABAYA

JIIS: Jurnal Ilmiah Ibnu Sina, 2023
Favipiravir merupakan antivirus untuk pengobatan COVID-19 karena mekanisme kerja obat atau efektivitasnya yang baik pada pasien COVID-19 dengan atau tanpa pneumonia.
Rika Yulia, Fauna Herawati, Klara Rosjuita Hima, Ruddy Hartono, Puri Safitri Hanum   +4 more
doaj   +1 more source

Favipiravir Pharmacokinetics in Ebola-Infected Patients of the JIKI Trial Reveals Concentrations Lower Than Targeted [PDF]

, 2017
In 2014-2015, we assessed favipiravir tolerance and efficacy in patients with Ebola virus (EBOV) disease (EVD) in Guinea (JIKI trial). Because the drug had never been used before for this indication and that high concentrations of the drugs were needed ...
Mentré, F, Pastorino, Boris, Raoul, Hervé, Anglaret, Xavier, Bore, JA, Malvy, D, France Mentré (238333), Laouénan, Cédric, Caroline Carbonnelle, Baize, Sylvain, Carbonnelle, Caroline, Xavier Anglaret, Cédric Laouénan (3776026), Anne Rodallec (3776029), Anne Rodallec, Denis Malvy, Mamoudou N. Conde (2548990), Denis Malvy (47735), Thi Huyen Tram Nguyen, Madelain, V, Anglaret, X, Nguyen, Thi Huyen Tram, Mamoudou N. Conde, Boris Pastorino, Xavier Anglaret (150373), Joseph Akoi Bore (2549020), Sissoko, Daouda, Nguyen, TH, Malvy, Denis, Madelain, Vincent, Raoul, H, Xavier de Lamballerie (95840), null null, Anne-Marie Taburet, Hervé Raoul, Vincent Madelain (3776032), Bore, Joseph Akoi, Conde, MN, Frédéric Jacquot (2825714), Pastorino, B, Anne-Marie Taburet (288246), Jean-Luc Gala, Sara Carazo (2549050), Sylvain Baize, Gala, JL, Sissoko, D, Jacquot, Frédéric, Géraldine Piorkowski (800529), Carazo, S, Mamoudou N Conde, Cédric Laouénan, Géraldine Piorkowski, Piorkowski, Géraldine, Conde, Mamoudou N, Carbonnelle, C, Xavier de Lamballerie, Daouda Sissoko (95574), France Mentré, Conde, Mamoudou, Carazo, Sara, Mentré, France, Rodallec, A, Caroline Carbonnelle (2549053), Guedj, J, Thi Huyen Tram Nguyen (3776035), Hervé Raoul (288207), de Lamballerie, X, Daouda Sissoko, Boris Pastorino (322367), Jérémie Guedj (2549236), Jean-Luc Gala (396991), Jacquot, F, Vincent Madelain, Sara Carazo, Rodallec, Anne, Taburet, Anne-Marie, de Lamballerie, Xavier, Taburet, AM, JIKI study group, Sylvain Baize (240459), Baize, S, Guedj, Jérémie, Piorkowski, G, Laouénan, C, Joseph Akoi Bore, Jérémie Guedj, Gala, Jean-Luc, Frédéric Jacquot   +87 more
core   +1 more source

Conventional and synchronous spectrofluorometric determination of the recently administered drugs for treatment of COVID-19 favipiravir and apixaban

Scientific Reports, 2022
COVID-19 is a fast-spreading pandemic that is caused by SARS-CoV-2 viral pathogen. Combination therapy of the antiviral favipiravir and the anticoagulant apixaban is one of the efficient treatment regimens.
Heba Samir Elama, Abdallah M. Zeid, Shereen M. Shalan, Yasser El-Shabrawy, Manal I. Eid   +4 more
doaj   +1 more source

Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis

BMC Infectious Diseases, 2021
Background Favipiravir possesses high utility for treating patients with COVID-19. However, research examining the efficacy and safety of favipiravir for patients with COVID-19 is limited.
Toshie Manabe, Dan Kambayashi, Hiroyasu Akatsu, Koichiro Kudo   +3 more
doaj   +1 more source

Development and Validation of HPLC-UV Method for the Determination of Favipiravir in Human Plasma

Разработка и регистрация лекарственных средств, 2022
Introduction. Coronavirus disease (COVID-19) is an acute infectious disease caused by SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2).
T. N. Komarov, P. K. Karnakova, O. A. Archakova, D. S. Shchelgacheva, N. S. Bagaeva, I. E. Shohin, K. Ya. Zaslavskaya, P. A. Bely   +7 more
doaj   +1 more source

Unveiling the Potential of B₃O₃ Nanoflake as Effective Transporter for the Antiviral Drug Favipiravir: Density Functional Theory Analysis

Molecules, 2023
In this study, for the first time, boron oxide nanoflake is analyzed as drug carrier for favipiravir using computational studies. The thermodynamic stability of the boron oxide and favipiravir justifies the strong interaction between both species.
Muhammad Nauman Zahid, Naveen Kosar, Hasnain Sajid, Khalid Elfaki Ibrahim, Mansour K. Gatasheh, Tariq Mahmood   +5 more
doaj   +1 more source

Evaluation of Nephrotoxic Properties of Favipiravir Using the RPTEC cell model

Безопасность и риск фармакотерапии, 2023
Scientific relevance. Favipiravir is an antiviral RNA polymerase inhibitor used to treat COVID-19. An adverse drug reaction associated with the use of favipiravir is renal disorder.Aim.
V. A. Evteev, I. S. Semenova, N. D. Bunyatyan, A. B. Prokofiev   +3 more
doaj   +1 more source